[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617145":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":25,"locations":34,"responsibleParty":48,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"30 families",null,"patient + parents+ siblings",[13,14],"Genetic: targeted gene panels analysis","Genetic: whole genome analysis",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"GENETIC","targeted gene panels analysis","The following gene panels will be analyzed : pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"whole genome analysis","Family-based identification of dominant or recessive potentially pathogenic variants.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Prof. Dr. med Valérie A McLIn, MD","CONTACT","+41223724545","valerie.mclin@hug.ch",{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},"Dr. phil. nat Isabelle Schepens, PhD","isabelle.schepens@hug.ch",[35],{"facility":36,"status":10,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":10},"University Hospitals Geneva \u002F University of Geneva","Geneva","Canton of Geneva","1205","Switzerland","CH",{"type":43,"coordinates":44},"Point",[45,46],6.14569,46.20222,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Prof. Valérie Mc Lin","Prof. Dr. Med.","100617145","genetic-hallmarks-of-patients-with-congenital-portosystemic-shunts-and-portopulmonary-hypertension-100617145",false,"NCT07314814","Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension","Gen-PoPH-CPSS","Inclusion Criteria:\n\n* Patient is a participant to the IRCPSS with history of PoPH\n* Trios composed of CPSS PoPH patients and their parents (trios are mandatory)\n* Brother\u002Fsister of an enrolled patient\n* Trios accept to provide biological samples (blood), sign the inform consent.\n* Siblings and\u002For siblings' legal representatives accept to provide biological samples (blood), sign the inform consent.\n\nExclusion Criteria:\n\n* Trio condition is not met.\n* No genuine parent-offspring trios (check for medically assisted procreation with donors, and adoption)\n* For siblings, half-brothers or half-sisters are excluded, as well as adopted children, or children issued from medically assisted procreation with donors.\n* Secondary portosystemic shunts\n* The refusal by the patient or the patient's legal representatives to provide biological samples or agree with the proposed procedure or after voluntary withdrawal from the project.\n* The refusal of one of the parents to provide biological samples or to agree with the proposed procedure or after voluntary withdrawal from the project.",true,"ALL","1 Day","99 Years",{"count":64,"type":65},120,"ESTIMATED","OBSERVATIONAL","Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation. Such liver bypass can cause several health problems, one of the most severe being portopulmonary hypertension (PoPH).\n\nThe goal of this study is to identify pathogenic and potentially pathogenic genetic variants in patients who have both CPSS and PoPH. Future research will assess the contribution of these genetic variants to the development of PoPH.\n\nThe long-term goal is to use genetic information to identify patients with congenital portosystemic shunts (CPSS) or chronic liver disease who are at risk of developing PoPH to offer anticipatory management.\n\nChildren and adult patients with both CPSS and PoPH, as well as their close relatives (patient's parents and siblings) can take part in the study. Genetic variations within each family will be studied.",[69,70,71],"Portopulmonary Hypertension","Pulmonary Arterial Hypertension (PAH)","Congenital Portosystemic Shunt",[73,74,75,76,77,78],"CPSS","PoPH","PAH","Genetic","Genomic","IRCPSS","NOT_YET_RECRUITING","2026-01-15",{"date":82,"type":83},"2026-01-20","ACTUAL",{"date":85,"type":65},"2026-02-01",{"date":87,"type":65},"2030-01-31",{"name":50,"class":6},1]